Spinifex's Neuropathic Pain Drug Proves Mettle in Phase II
LONDON – Spinifex Pharmaceuticals announced positive Phase II results of EMA401 in controlling neuropathic pain following herpes zoster (shingles) infection, and the company is now weighing the commercialization strategy for the product.
The study delivers the first clinical proof of efficacy in a new approach to treating neuropathic pain by blocking angiotensin II Type 2 (AT2), a receptor found on neuronal cells that perpetuates the hypersensitive response that is the hallmark of that form of chronic pain.
Tom McCarthy, CEO, said while there are existing treatments for neur
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter